NuCyRNA Therapeutics

NuCyRNA Therapeutics is excited to present our next-generation RNA-targeting technology at the SCbioDrive Accelerator Investor Showcase on Nov 20 in Charleston, SC. Join us to explore investment opportunities in innovative therapeutics aimed at tackling neurodegenerative diseases in our rapidly aging population! Thank you for your support! SCbio, Eli Lilly and Company, MassBio, Deloitte, @morningside ventures Charles River Laboratories, Inspire Agency, Medpoint, LLC

NuCyRNA Therapeutics has been recognized by the Platinum Program, which is supported by Mission BioCapital, Eli Lilly and Company, and ONO PHARMA USA. We are developing next-gen oligonucleotide therapeutics, with initial focus on neurodegeneration. https://lnkd.in/eEbDjPhA

Neurotoxicity is a significant challenge in oligonucleotide therapeutics for neurodegenerative diseases. Our co-founder, Dr. Jonathan Watts just published their work on characterizing and mitigating the acute neurotoxicity induced by antisense oligonucleotide (#ASO) on Molecular Therapy (Cell Press), a prestigious journal in the field of gene and cell therapy (#CGT). With the expertise from Dr. Jonathan Watts and the rest of co-founders, NuCyRNA Therapeutics aims to transform RNA-targeting therapeutics by our next-gen oligonucleotide technology, starting in neurodegenerative diseases such as #ALS. #Neurotoxicity #oligonucleotide, RNA Therapeutics Institute at UMass Chan Medical School

NuCyRNA Therapeutics is hiring a Preclinical Development Lead/Project Manager with a strong background in preclinical oligonucleotide drug development in neuroscience. Welcome to share this post with your network! Application link: https://lnkd.in/erdK6N8k Applications are reviewed on a rolling basis, so we encourage you to submit your application as early as possible. We aim to make a decision by Nov 22. If the application link is active, we are still accepting applications. #ProjectManager, #oligonucleotide, #ASO, #neuroscience, #ALS

NuCyRNA Therapeutics is still seeking a talent with background in molecular biology and iPSC-derived neurons at the Associate Scientist/Scientist level. Welcome to share this post with your network!

Congrats to Dr. Victor Ambros & Dr. Gary Ruvkun for receiving The Nobel Prize in recognition of their groundbreaking research in microRNA. RNA-targeting approaches present a promising avenue for expanding the spectrum of druggable targets and addressing challenges that have proven intractable to traditional small molecule strategies. Standing on giants shoulders, NuCyRNA Therapeutics aims to transform RNA-targeting therapeutics, with the initial focus on neurodegenerative diseases. Email info@nucyrnatx.com if you want to learn more about us.

Thank you to our #MassBioDrive Spring 2024 cohort mentors! Gadi G. Bornstein, Ph.D. | Michael Boss | Atul Deshpande Ph.D., MBA, A-PMP | Jean Ge, PhD | Alex Goddard, Ph.D. | David Hayes | Arthur Hiller | Alexis Hofherr | Dominic McDonald | Shreya M. | Amber Meriwether | Catherine Mesner | Carles Monterrubio, PhD | Neal Muni | Joseph Murphy| Jean-Noël Pellegrin | Roydon Price | Mousumi Sannigrahi, PhD MBA | John Tagliamonte | Po-Jen (Will) Yen You enrich this program and make a positive impact on our participants: DoriNano, Hestia Therapeutics, Koi Biotherapeutics, Nucyrna Therapeutics, and Sphinxion Therapeutics. If you're interested in sharing your expertise with a future MassBioDrive cohort, apply to become a mentor here: https://lnkd.in/e7Mg6vwK

Nucyrna Therapeutics just graduated from the MassBioDrive mentorship program! Building on our next-gen oligonucleotide platform, we've identified our lead program as #ALS and work towards a development candidate in 2026. Big shout to Nucyrna Therapeutics team, Jonathan Watts, Evangelos Kiskinis, and Joseph Klim. Congrats to these incredible entrepreneurs in the same cohort: Yang (Claire) Zeng, Anita Scheuber, Julie Saba, Hamid Mahini, Mohammad Rashidian! Very grateful towards the support from MassBio team (Nikki Taylor Seiler, MHA, Caroline Pepek, Jason Cordeiro), our incredible mentors (Alex Goddard, Ph.D., Jessica O'Leary, John Tagliamonte, Neal Muni, Po-Jen (Will) Yen), and coaches (Dan Goddard, Jennifer Fang, Chris McAndrew, Chris Garabedian, Jayanth Batchu, Richard Dennett, etc)! Photo credit to John Wilcox Photography.

It's a blast for Nucyrna team attending the Target ALS Annual meeting this week! We are inspired by the efforts led by Target ALS team (Manish Raisinghani, Dan Doctoroff, Amy Easton, et al) and research advancing ALS therapeutics development. We are working relentlessly to develop disease-modifying therapeutics to ALS built on our next-gen oligonucleotide technology.

Nucyrna is honored to be featured by MassBio!